Our clinics and doctors do not work with German statutory health insurance (Krankenkassen)
Organization of treatment and rehabilitation in Germany.
Complete medical support.
English English ▼
+49 176 17917001 All departments

Cancer Diagnostics in Germany

Cancer diagnostics in Germany is a set of high-tech examinations that detect cancer at an early stage, when treatment is most effective, and determine its exact type and extent. German cancer centres use PET-CT, 3-Tesla MRI, image-guided biopsy and molecular tumour analysis; certified centres work according to national guidelines and discuss every case in a tumour board.

Why early cancer diagnosis matters

Cancer diagnostics in Germany

Cancer is the second most common cause of death worldwide, yet many cancers are curable when detected early:

  • Breast cancer – 5-year survival in stage I is about 99 %;
  • Prostate cancer – in the localised stage survival is close to 100 %;
  • Colorectal cancer – in an early stage it is cured in about 90 % of cases;
  • Melanoma – after timely removal about 98 % of patients recover.

Regular screening finds a tumour before symptoms appear, when it is small and has not spread.

Methods of cancer diagnostics

Imaging

  • PET-CT – the standard method for detecting metastases and determining the extent of the disease;
  • MRI – detailed images of soft tissues, the brain and the pelvic organs;
  • CT – bones, lungs and abdomen;
  • Ultrasound – initial diagnosis and guidance of biopsies;
  • Mammography – breast cancer screening;
  • Bone scintigraphy – search for bone metastases.

Laboratory tests

  • tumour markers in the blood (mainly for monitoring treatment);
  • liquid biopsy – tumour DNA and circulating tumour cells in the blood;
  • genetic tests for hereditary predisposition.

Tissue diagnostics

  • ultrasound- or CT-guided biopsy;
  • histology;
  • immunohistochemistry;
  • molecular genetic analysis of the tumour.

What does a PET-CT scan show?

PET-CT combines positron emission tomography with computed tomography and is one of the most informative methods in oncology. It makes it possible to:

  • find the primary tumour and metastases from about 5–7 mm in size;
  • assess the metabolic activity of a lesion;
  • determine the stage of the disease;
  • evaluate the response to treatment;
  • detect a recurrence early.

Before the scan the patient receives a radiotracer, most often 18F-FDG, which accumulates in tumour cells with increased metabolism; the whole-body scan follows after about 60 minutes. For prostate cancer, PSMA-PET-CT is used, and for neuroendocrine tumours DOTATATE-PET-CT.

Biopsy and histology

A biopsy – taking a tissue sample for microscopic examination – is the decisive step: only the histological report confirms or rules out cancer.

  • Needle biopsy – fine-needle sampling under ultrasound or CT guidance;
  • Core biopsy – a thicker needle removes a cylinder of tissue;
  • Endoscopic biopsy – during gastroscopy, colonoscopy or bronchoscopy;
  • Surgical biopsy – removal of part or all of the lesion.

German laboratories also perform immunohistochemistry (tumour receptors, e.g. hormone receptors and HER2) and molecular profiling to select targeted therapy and immunotherapy.

Are tumour markers useful?

Tumour markers are proteins produced by tumour cells or by the body in response to cancer. They are mainly used to monitor treatment and detect recurrence. Tumour markers are not suitable for screening healthy people: a normal value does not rule out cancer, and an elevated value is often caused by benign conditions. The exception is PSA for prostate cancer, which is measured after an informed discussion with the doctor.

MarkerTumour type
PSAprostate cancer
CA 125ovarian cancer
CA 19-9pancreatic and gastrointestinal cancer
CEAcolorectal and lung cancer
AFPliver cancer, germ cell tumours
CA 15-3breast cancer

Genetic testing

  • BRCA1/BRCA2 – mutations that increase the risk of breast and ovarian cancer;
  • Lynch syndrome – predisposition to colorectal and endometrial cancer;
  • Molecular tumour profiling – mutations that determine the choice of targeted drugs;
  • Liquid biopsy – tumour DNA in the blood for monitoring.

Cancer screening programmes

In Germany, statutory early-detection programmes start at fixed ages: skin cancer screening from 35, cervical cancer screening from 20, colorectal cancer screening from 50, prostate examination for men from 45 and mammography screening for women aged 50 to 75. Private clinics offer extended programmes:

Breast cancer screening

Mammography, breast ultrasound and a consultation; women with BRCA mutations additionally receive breast MRI.

Prostate cancer screening

PSA test after informed discussion, examination and, if indicated, prostate MRI and MRI/ultrasound fusion biopsy.

Gastrointestinal cancer screening

Colonoscopy or a stool test for occult blood, gastroscopy if indicated; recommended from age 50, earlier if relatives have had colorectal cancer.

Lung cancer screening

Low-dose CT of the chest for long-term heavy smokers aged 50 to 75 after consultation with a pulmonologist.

How much does cancer diagnostics cost in Germany?

Cancer diagnostics in Germany costs from about 300 € for an oncologist consultation to 3,500 € and more for a comprehensive screening programme; a whole-body PET-CT costs from 2,500 €. The final price depends on the examinations the doctor considers necessary.

ExaminationCost
Oncologist consultationfrom 300 €
Tumour marker panelfrom 250 €
Whole-body PET-CTfrom 2,500 €
MRI (one region)from 800 €
Ultrasound/CT-guided biopsyfrom 1,500 €
Histology + immunohistochemistryfrom 600 €
Molecular profilingfrom 3,000 €
Comprehensive cancer screeningfrom 3,500 €
Have questions? Free consultation
Call or write via Telegram / WhatsApp:
telegram +49 176 17917001 whatsapp

Or send us a message:

By clicking "Submit Application", you agree to the processing of personal data

Patient Relations Specialist Svetlana Malygina Your questions will be answered by Patient Relations Specialist Svetlana Malygina

Prepared by the Doktor München editorial team.
Updated:
This information is for reference only and does not replace a consultation with a doctor.